Altus Spine Announces Private Label Partnership with Nanovis® Spine
West Chester, PA – July 14th, 2022 /OrthoSpineNews/– Altus Spine, a leader in the development and innovation of medical devices used in spinal correction surgery, announces private label partnership with Nanovis® Spine to further strengthen and expand their bioceramic nanotube surface technologies throughout their portfolio.
Nanovis, a technology-driven company committed to discovering unmet clinical needs, develops innovative and enabling solutions and validates new technologies for clinical and market acceptance. After considerable research to find the right company and system, Nanovis subsidiary, Nanovis Spine chose to private label the Altus Spine pedicle screw systems as a foundation to commercialize Nano FortiFix®, the only FDA designated and cleared nanotechnology pedicle screw system on the market today. There are three systems that were made available as the result of this partnership – Nano FortFix® (c) Cortical, Nano FortiFix® (s) Standard, and Nano FortiFix® (MIS) Minimally Invasive.
“Nanovis Spine is excited to be working with Altus Spine and we appreciate the opportunity to partner with a great company, team, and system to commercialize our Nano FortiFix® pedicle screw systems,” said Jeff Shepherd, Nanovis Chief Commercial Officer, “As the result of launching Nano FortiFix® in Q3 2021, Nanovis Spine has achieved a record sales month, a record sales quarter, and is on pace to achieve a record sales year. Nano FortiFix® has been the leading revenue product for Nanovis Spine since our launch and we are gaining new surgeon, distributor, and hospital customers each month because of the nanotechnology designation, data, and meaningful differentiation on pedicle screws.”
The nanoVIS Ti Surface Technology TM platform has continued to out-perform other surfaces in pre-clinical studies and is demonstrating strong biologic fixation in clinical settings. The platform technology continues to show promise in in-vivo studies to reduce bacteria colonization without sacrificing biologic implant fixation.
“Our team is thrilled to partner with such an innovative company that is utilizing our pedicle screw systems to expand on the surface capabilities,” said Michael Fitzgerald, Altus Spine Founder and CEO. “This partnership is a huge step in the continual expansion using the latest technologies in unique surface architectures for medical devices – a game changer when it comes to safely accelerating fixation,” said Fitzgerald.
For more information, contact us at email@example.com
*Altus Spine is not the owners/producers of the micro/nanotechnology.
Nanovis performs and owns all nanotechnology-related procedures.
Based in West Chester, PA, Altus Spine is dedicated to creating the next generation of medical devices. Altus strives to improve patient care by designing and manufacturing products to meet the highest standards in an ever changing and evolving field. Implemented and used by over 100 hospitals across the United States, Altus is among the fastest growing spinal implant companies in the world. For additional information, or to inquire about distribution opportunities, please contact us at firstname.lastname@example.org.
Nanovis is a technology-driven company committed to discovering unmet clinical needs, developing innovative and enabling solutions, and validating new technologies for clinical and market acceptance. Founded in 2008, Nanovis has become the market leader in nanotechnology used to improve the biological response to orthopedic implants. Through its subsidiary Nanovis Spine, Nanovis commercialized its proprietary and best-in-class nanoVIS Ti Surface Technology™ on a family of spinal implants to include Open and Minimally Invasive Pedicle Screws (Nano FortiFix®), and PEEK Titanium Hybrid Interbodies (Nano FortiCore®), enhanced with Osteosync, a technology licensed from Sites Medical. Nanovis continuously looks for opportunities to commercialize its nanoVIS Ti Surface TechnologyTM in all areas of orthopedics.
Forward Looking Statements
All statements made in the above press release, with the exception of historical fact, may be forward-looking statements that include risk, uncertainty, and assumptions. These factors could cause Altus Spine’s results to differ from those predicted if they do not occur as expected. These uncertain factors include, but are not limited to: acceptance and clearance of the company’s surgical products and procedures, development of new products and procedures, innovations and alterations to existing products and procedures, clinical and statistical verification of the success using Altus Spine’s products, company’s ability to maintain and monitor inventory as it releases new products, its ability to hire and retain personnel, and any other risks stated in prior or subsequent news releases. All risks and potential complications can be found in our most recent 510(k) report from the Food and Drug Administration (FDA). Given the constantly changing market, readers are encouraged to not place undue reliance on forward-looking statements. Altus Spine assumes no obligation to update forward-looking statements as these changes occur, or as events and circumstances are altered, after the date they are posted.